(Q33943410)

30 July 2017

1 reference

title

The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system (English)

1 reference

30 July 2017

0 references

1

Hartung HP

1 reference

30 July 2017

Kieseier BC

2

1 reference

30 July 2017

1 July 2000

1 reference

Journal of Neuroimmunology

30 July 2017

1 reference

30 July 2017

107

1 reference

30 July 2017

140-147

1 reference

30 July 2017

2

1 reference

Oligodendrocyte-type 2 astrocyte progenitors use a metalloendoprotease to spread and migrate on CNS myelin

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Proteolytic remodeling of extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases degrade myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Human progelatinase A can be activated by matrilysin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

The Expression of Tissue-type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

MS: a CNS and systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Circulating adhesion molecules and inflammatory mediators in demyelination: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Autoimmune responses in peripheral nerve

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase expression during experimental autoimmune neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases in inflammatory demyelination: targets for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Structural biochemistry and activation of matrix metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Clinical importance of metalloproteinases and their inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Regulation of matrix metalloproteinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Interaction of alpha 2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Metalloproteinases and their tissue inhibitors in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Regulation of tissue inhibitor of matrix metalloproteinase expression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinase degradation of extracellular matrix: biological consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

The role of T cells in multiple sclerosis: implications for therapies targeting the T cell receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Membrane proteases in focus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

The family of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

Matrix metalloproteinases and diseases of the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900225-3

7 January 2021

10.1016/S0165-5728(00)00225-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10854648